Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 107 of 1,261
  1. US 12030910

    Compounds and methods for the modulation of proteins

    Ionis Pharmaceuticals, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  2. US 12029759

    Compositions and methods for treating neurological disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  3. US 12029777

    Serine proteinase inhibitors: Serp-1 and Serp-1 RCL-derived peptides effect on microbiome composition and uses thereof

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  4. US 12029782

    MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof

    Cue Biopharma, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  5. US 12031147

    Adeno-associated virus virions with variant capsids and methods of use thereof

    The Regents of the University of California Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  6. US 12031133

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  7. US 12031132

    Systems and methods for the treatment of hemoglobinopathies

    Editas Medicine, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  8. US 12030953

    Chimeric antigen receptors, compositions, and methods

    Regents of the University of Minnesota Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  9. US 12030935

    Anti-PDGF-B antibodies and pharmaceutical composition thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  10. US 12029794

    Virus-like particle conjugates for diagnosis and treatment of tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Serv Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  11. US 12029788

    Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that is an anti-GDF8 antibody

    REGENERON PHARMACEUTICALS, INC. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  12. US 12029732

    Treatment of vascular and lymphatic disease

    The Regents of the University of Colorado, a Body Corporate Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  13. US 12029787

    Method for generating recombinant poxviruses

    UNIVERSITY OF CONNECTICUT Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  14. US 12030940

    Immunotherapeutic tumor treatment method

    Nektar Therapeutics Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  15. US 12029816

    Compositions and methods of making brittle-matrix particles through blister pack freezing

    The Board of Regents of the University of Texas System Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  16. US 12029745

    Effects of LGM2605 on a primate model of asthma

    The Regents of the University of California Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  17. US 12031150

    Methods, compositions and kits for increasing genome editing efficiency

    Vertex Pharmaceuticals Incorporated Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  18. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  19. US 12031008

    Dendritic macroporous hydrogels prepared by crystal templating

    The Board of Regents of the University of Texas System Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  20. US 12030958

    Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides

    The Regents of the University of Colorado Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  21. US 12030911

    Synthesis and biological activity of phosphoramidimidate and phosphoramidate DNA

    The Regents of the University of Colorado, a Body Corporate Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  22. US 12029755

    Carbon monoxide-based therapies and implantable devices for the treatment of vascular disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  23. US 12029577

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted
  24. US 12030925

    Methods of treating hemophilia A

    BIOVERATIV THERAPEUTICS INC. Β· Granted Jul 9, 2024 Β· Expires Jul 4, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.